Vergoeding 2014-2018 voor ATC-subgroep C09CA : Angiotensine-ii-antagonisten
- Raming voor de totale Zvw-populatie
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| C09CA01 Losartan (Cozaar ®) | 2.836.700 | 2.629.600 | 2.366.900 | 2.558.600 | 3.068.300 |
| C09CA02 Eprosartan (Teveten ®) | 609.760 | 559.570 | 408.400 | 377.310 | 361.770 |
| C09CA03 Valsartan (Vagrecor ®) | 3.939.800 | 3.216.600 | 3.109.200 | 3.216.100 | 3.580.200 |
| C09CA04 Irbesartan (Aprovel ®) | 4.118.200 | 3.570.500 | 2.985.600 | 2.522.200 | 2.641.600 |
| C09CA06 Candesartan (Atacand ®) | 1.692.000 | 1.236.600 | 1.109.000 | 1.085.000 | 1.215.300 |
| C09CA07 Telmisartan (Micardis ®) | 2.919.600 | 1.119.300 | 898.810 | 798.200 | 776.520 |
| C09CA08 Olmesartan (Olmetec ®) | 2.764.700 | 2.722.500 | 2.608.800 | 1.839.300 | 685.170 |
| C09CA09 Azilsartanmedoxomil | 10.319 | 920 | . | . | . |
| Totaal | 18.891.079 | 15.055.590 | 13.486.710 | 12.396.710 | 12.328.860 |